Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.
about
Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus.Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination.Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations.The inability of wild-type rabies virus to activate dendritic cells is dependent on the glycoprotein and correlates with its low level of the de novo-synthesized leader RNA.Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and catsChimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.Differential Host Immune Responses after Infection with Wild-Type or Lab-Attenuated Rabies Viruses in Dogs.λ-Carrageenan P32 Is a Potent Inhibitor of Rabies Virus InfectionPostexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the Central Nervous System (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues.Critical Role of K1685 and K1829 in the Large Protein of Rabies Virus in Viral Pathogenicity and Immune EvasionInfection with street strain rabies virus induces modulation of the microRNA profile of the mouse brain.A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.Rabies virus glycoprotein is an important determinant for the induction of innate immune responses and the pathogenic mechanisms.Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs.Genome-Wide Transcriptional Profiling Reveals Two Distinct Outcomes in Central Nervous System Infections of Rabies Virus.Role of the blood-brain barrier in rabies virus infection and protection.A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B CellsDevelopments in rabies vaccines.Recombinant rabies virus expressing IL-15 enhances immunogenicity through promoting the activation of dendritic cells in mice.Immunological aspects of rabies: a literature review.Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination.Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses.Comparison of the immunogenicity of two inactivated recombinant rabies viruses overexpressing the glycoprotein.Phosphoprotein Gene Contributes to the Enhanced Apoptosis Induced by Wild-Type Rabies Virus GD-SH-01 In Vitro.Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene.An optimized HMGB1 expressed by recombinant rabies virus enhances immunogenicity through activation of dendritic cells in mice.Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine.Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine
P2860
Q34043161-B7A71F73-E4DF-40EF-88BE-CAFB68AD7236Q34529895-58D6110A-8297-448F-AD00-98B8A1663AF8Q34735086-AAE9C8E2-357F-4926-B955-E986566CACFEQ35115568-EB1C3717-E2EF-462A-95B7-213D7E4ACC7EQ35140435-AF0BB198-B40A-4889-93FE-53F87148CF60Q35232804-B5DF2404-281C-46CD-AB76-CC8D834CCD84Q35751466-818C74D5-C2AF-484E-93C7-D48E26B77B4EQ35806354-DE4C348C-1CB0-4C98-8593-D12FBBE7CF85Q35826226-FADDE24E-DCBB-41DB-B35B-27EE3A1ACC04Q36433882-E0F93792-8812-43A4-AB2C-0C4E5F90D393Q36547745-787DDBAD-EF76-4575-AE19-B1AC12953B98Q36559952-B9A7C2B7-F26F-4E47-A159-8123298C6FB1Q36598941-D6ED4786-BDB8-49A0-BC3F-967CAA2FA187Q36629350-C79EDBB8-102C-4F8A-A90F-469741F3D6DEQ36913970-5FEF2E86-51D1-448C-8CB8-0E7FCB02C355Q36922970-DB89A800-9225-4060-B3BD-5D5DC0ED7CE9Q37548524-8D45416C-8995-49FC-8F27-0F23A8B294C8Q37593174-A3F0AE83-19A0-4E96-B6C1-87C357A49178Q38031922-0B42742F-C377-4C16-AC6D-B42104E49B51Q38598361-318FD2F4-533F-4B09-8A16-23185BC43990Q38654706-9226617F-D0DD-4183-9ED6-5808CCB30824Q38720666-2A5A0FDB-4F93-4BB4-A56C-D33169CC171DQ40226015-6A52EE96-9BD9-47DE-B58B-E9C4DEE272DBQ40606570-3A62CA29-5C91-4E1A-8DDB-8E7379DA11D7Q41454399-EB66748F-46BC-4906-A569-DE6A131431C7Q42158908-742B5B16-E312-4755-A6D3-DF594656ACE5Q45034708-440485E2-FD6B-49EF-866E-5508F386ADB8Q49773390-5F01ED81-5A1C-4050-8C80-1332AFF89C2FQ56967894-D2A3BF2E-C4AE-4F8F-A9DE-3C5DD11EEBD2
P2860
Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@ast
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@en
Expression of MIP-1alpha
@nl
type
label
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@ast
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@en
Expression of MIP-1alpha
@nl
prefLabel
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@ast
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@en
Expression of MIP-1alpha
@nl
P2093
P2860
P356
P1433
P1476
Expression of MIP-1alpha (CCL3 ...... g dendritic cells and B cells.
@en
P2093
Harufusa Toriumi
Hualei Wang
Kinjiro Morimoto
Xiaofeng Guo
P2860
P304
P356
10.1128/JVI.00326-10
P407
P577
2010-06-30T00:00:00Z